Sustained‐Release Ulcer‐Protective Microarray Patch With Dihydrocapsaicin for Diabetic Wound Regeneration

Diabetic foot ulcers (DFUs) present a persistent clinical challenge, posing a significant and ongoing threat to patient health. Current treatment strategies are failing to concurrently address the excessive oxidative stress and impaired angiogenesis during whole‐course management of diabetic wounds. To overcome these limitations, this study developed an innovative microneedle (MN)‐based drug delivery system incorporating cerium‐based metal‒organic frameworks (MOFs) loaded with dihydrocapsaicin (DHC). Fabricated from a Gelatin Methacryloyl (GelMA) hydrogel, the resulting MN‐MOF@DHC system exhibited a sustained release profile of DHC that nearly covered the whole‐course management of diabetic wounds. Our results revealed that the MN‐MOF@DHC system effectively reduced the levels of reactive oxygen species (ROS), promoted the transformation of macrophage phenotypes from the pro‐inflammatory M1 subtype to the anti‐inflammatory M2 subtype, and significantly enhanced endothelial cell angiogenesis. These combined actions markedly accelerated wound closure. Collectively, the advanced MN platform offers a highly promising strategy for the treatment of DFUs.